Abstract | AIMS: METHODS AND RESULTS: In the Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia ( PRODIGY) trial, a total of 1465 (74.3%) patients presented ACS whereas 505 (25.7%) had SCAD and were randomized to 6- or 24-month DAPT. At 24 months, the composite of death, myocardial infarction (MI), or cerebrovascular accident (CVA) did not differ between the long- and short-term DAPT arms in both ACS (11.1 vs. 11.7%; P = 0.67) and SCAD (7.5 vs. 4.8%; P = 0.21) patients, respectively. Long-term DAPT was associated with a 75% increase of Bleeding Academic Research Consortium (BARC)-class 2, 3, or 5 bleeding in ACS [7.1 vs. 4.1%; hazard ratio (HR) 1.75, 95% confidence interval (CI) 1.11-2.74, P = 0.015; number needed to treat for harm (NNTH): 33.3] and a five-fold increase in SCAD (8.2 vs. 1.6%; HR 5.37, 95% CI 1.84-15.74, P = 0.002; NNTH: 15.1) patients, with a borderline quantitative interaction (PINT = 0.056). As a result, net adverse cardiovascular events (death, MI, CVA, BARC class 2, 3, or 5 bleeding) were more than doubled in SCAD patients receiving 24-month DAPT, whereas they did not differ in ACS patients (PINT = 0.024). CONCLUSIONS: This analysis suggests that clinical presentation may be a treatment modifier with respect to DAPT duration after stenting consistent with the hypothesis that SCAD-but not ACS-patients are exposed to a significant increase in bleeding and net adverse clinical events when treated with 24-month compared with 6-month therapy. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00611286. http://clinicaltrials.gov/ct2/show/NCT00611286?term= prodigy&rank=2.
|
Authors | Francesco Costa, Pascal Vranckx, Sergio Leonardi, Elisabetta Moscarella, Giuseppe Ando, Paolo Calabro, Giuseppe Oreto, Felix Zijlstra, Marco Valgimigli |
Journal | European heart journal
(Eur Heart J)
Vol. 36
Issue 20
Pg. 1242-51
(May 21 2015)
ISSN: 1522-9645 [Electronic] England |
PMID | 25718355
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: [email protected]. |
Chemical References |
- Platelet Aggregation Inhibitors
- Clopidogrel
- Ticlopidine
- Aspirin
|
Topics |
- Acute Coronary Syndrome
(mortality, therapy)
- Aged
- Aspirin
(administration & dosage)
- Clopidogrel
- Coronary Artery Disease
(mortality, therapy)
- Drug Therapy, Combination
- Female
- Hemorrhage
(chemically induced)
- Humans
- Hyperplasia
(etiology)
- Male
- Myocardial Infarction
(etiology, mortality)
- Percutaneous Coronary Intervention
(methods, mortality)
- Platelet Aggregation Inhibitors
(administration & dosage)
- Prognosis
- Stents
- Stroke
(etiology, mortality)
- Ticlopidine
(administration & dosage, analogs & derivatives)
- Tunica Intima
(pathology)
|